Skip to content
zameds

Oxymetazoline (Zadin Nasal)

Oxymetazoline

Sandoz South Africa (Pty) Ltd

Registration

Applicant
Sandoz South Africa (Pty) Ltd
Registrations
4

Variants

ProductStrength and formRegistrationStatusScheduleLeaflets
Zadin 0,025 nasal spray

EACH 1,0 ml SOLUTION CONTAINS OXYMETAZOLINE 0,25 mg

0,025Spray44074944/16.1/0749RegisteredNot determinedNone
Zadin 0,05 % nasal spray

EACH 1,0 ml SOLUTION CONTAINS OXYMETAZOLINE 0,5 mg

0,05 %Spray44075044/16.1/0750RegisteredNot determinedNone
Zadin 0,025 nasal drops

EACH 1,0 ml DROPS CONTAINS OXYMETAZOLINE 0,25 mg

0,025Drops44075144/16.1/0751RegisteredNot determinedNone
Zadin 0,05 % nasal drops

EACH 1,0 ml DROPS CONTAINS OXYMETAZOLINE 0,5 mg

0,05 %Drops44075244/16.1/0752RegisteredNot determinedNone

Regulatory status

This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.

Listings for this ingredient that could not be applied to this product

  • S2: Oxymetazoline

    • except when intended for nasal use

    Consolidated Schedules 06 July 2026, line 2476

  • S1: Oxymetazoline

    • when intended for nasal use.

    Consolidated Schedules 06 July 2026, line 952

This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.

C16H24N2O260.37 g/mol

6-tert-Butyl-3-(4,5-dihydro-1H-imidazol-2-ylmethyl)-2,4-dimethylphenol

Drag to rotate. Structure from PubChem CID 4636.

SAHPRA documents

SAHPRA has not published a professional information or patient information leaflet for this product.

Background

Loading...
Loading Wikipedia summary

Research articles

Loading...
Loading PubMed articles